Descripción

Cognitive assessment scores from studies evaluating EGb 761 at 240 mg/day in patients with MCI, comparing treatment and placebo groups on standardized neuropsychological measures.

Figure 5

Chart

Source Paper

Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®).

Pharmaceuticals (Basel, Switzerland) (2021)

PMID: 33915701

DOI: 10.3390/ph14040305

Cite This Figure

![Figure 5: Cognitive assessment scores from studies evaluating EGb 761 at 240 mg/day in patients with MCI, comparing treatment and placebo groups on standardized neuropsychological measures.]()

> Source: Carlo Tomino et al. "Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®." *Pharmaceuticals (Basel, Switzerland)*, 2021. PMID: [33915701](https://pubmed.ncbi.nlm.nih.gov/33915701/)

<figure>
  <img src="" alt="Cognitive assessment scores from studies evaluating EGb 761 at 240 mg/day in patients with MCI, comparing treatment and placebo groups on standardized neuropsychological measures." />
  <figcaption>Figure 5. Cognitive assessment scores from studies evaluating EGb 761 at 240 mg/day in patients with MCI, comparing treatment and placebo groups on standardized neuropsychological measures.<br>  Source: Carlo Tomino et al. "Mild Cognitive Impairment and Mild Dementia: The Role of Ginkgo biloba (EGb 761®." <em>Pharmaceuticals (Basel, Switzerland)</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/33915701/">33915701</a></figcaption>
</figure>

Evidencia relacionada

Ginkgo biloba para Age-Related Cognitive Decline

Calificación C · 40 estudios